These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1539 related articles for article (PubMed ID: 11842390)
41. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Fisher RI Leuk Lymphoma; 2005 Nov; 46(11):1569-73. PubMed ID: 16236611 [TBL] [Abstract][Full Text] [Related]
42. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461 [TBL] [Abstract][Full Text] [Related]
43. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Dreger P; Rieger M; Seyfarth B; Hensel M; Kneba M; Ho AD; Schmitz N; Pott C Haematologica; 2007 Jan; 92(1):42-9. PubMed ID: 17229634 [TBL] [Abstract][Full Text] [Related]
44. Diffuse aggressive lymphoma. Fisher RI; Miller TP; O'Connor OA Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685 [TBL] [Abstract][Full Text] [Related]
45. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Wilson WH; Gutierrez M; O'Connor P; Frankel S; Jaffe E; Chabner BA; Grossbard ML Semin Oncol; 2002 Feb; 29(1 Suppl 2):41-7. PubMed ID: 11842388 [TBL] [Abstract][Full Text] [Related]
46. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858 [TBL] [Abstract][Full Text] [Related]
48. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients. Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525 [TBL] [Abstract][Full Text] [Related]
49. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma. Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178 [TBL] [Abstract][Full Text] [Related]
50. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E; Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102 [TBL] [Abstract][Full Text] [Related]
51. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Lefrère F; Delmer A; Suzan F; Levy V; Belanger C; Djabarri M; Arnulf B; Damaj G; Maillard N; Ribrag V; Janvier M; Sebban C; Casasnovas RO; Bouabdallah R; Dreyfus F; Verkarre V; Delabesse E; Valensi F; McIntyre E; Brousse N; Varet B; Hermine O Leukemia; 2002 Apr; 16(4):587-93. PubMed ID: 11960337 [TBL] [Abstract][Full Text] [Related]
52. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. Smith MR; Li H; Gordon L; Gascoyne RD; Paietta E; Forero-Torres A; Kahl BS; Advani R; Hong F; Horning SJ J Clin Oncol; 2012 Sep; 30(25):3119-26. PubMed ID: 22851557 [TBL] [Abstract][Full Text] [Related]
53. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Haioun C; Mounier N; Emile JF; Ranta D; Coiffier B; Tilly H; Récher C; Fermé C; Gabarre J; Herbrecht R; Morchhauser F; Gisselbrecht C Ann Oncol; 2009 Dec; 20(12):1985-92. PubMed ID: 19567453 [TBL] [Abstract][Full Text] [Related]
54. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073 [TBL] [Abstract][Full Text] [Related]
55. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951 [TBL] [Abstract][Full Text] [Related]
56. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W; Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739 [TBL] [Abstract][Full Text] [Related]
57. Blastoid mantle cell lymphoma presenting as acute leukemia: a case report. Dongre A; Kanchankar N; Deshmukh M; Wasnik D; Dongre T Pan Afr Med J; 2021; 39():150. PubMed ID: 34527166 [TBL] [Abstract][Full Text] [Related]
58. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Rapoport AP; Meisenberg B; Sarkodee-Adoo C; Fassas A; Frankel SR; Mookerjee B; Takebe N; Fenton R; Heyman M; Badros A; Kennedy A; Jacobs M; Hudes R; Ruehle K; Smith R; Kight L; Chambers S; MacFadden M; Cottler-Fox M; Chen T; Phillips G; Tricot G Bone Marrow Transplant; 2002 Feb; 29(4):303-12. PubMed ID: 11896427 [TBL] [Abstract][Full Text] [Related]
59. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. Freedman AS; Neuberg D; Gribben JG; Mauch P; Soiffer RJ; Fisher DC; Anderson KC; Andersen N; Schlossman R; Kroon M; Ritz J; Aster J; Nadler LM J Clin Oncol; 1998 Jan; 16(1):13-8. PubMed ID: 9440717 [TBL] [Abstract][Full Text] [Related]
60. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]